GSK Australia divestment of Kapanol Complete
GSK Australia’s divestment of the pain relief product Kapanol (morphine sulphate) to Mayne Pharma Group Limited (Mayne Pharma) was finalised today.
GSK Australia’s divestment of the pain relief product Kapanol (morphine sulphate) to Mayne Pharma Group Limited (Mayne Pharma) was finalised today.
Under the terms of the agreement, Mayne Pharma will acquire the Kapanol® trademark and related Australian assets.
Geoff McDonald, General Manager GSK Australia said, “This deal with Mayne Pharma brings to a close the divestment of our classic brands portfolio. We will now focus fully on bringing new medicines from our pipeline to Australian patients.”
Kapanol® is a modified release oral opioid used for the relief of chronic, moderate to severe pain.
